הכנסה תפעולית לפני ניכוי פחת: COMPASS Pathways PLC (CMPS)

COMPASS Pathways plc (CMPS) maintains its leadership through patents for synthetic psilocybin and its influence within US psychiatry. The EBITDA financial metric on the GURU.Markets chart confirms this stage, where 0.00 shows the value of this parameter. However, geopolitical tensions are hindering global therapy trials, although its status as the primary innovator in psychedelics ensures deep trust in the brand from the medical community.

Anticipation of Phase 3 clinical trial results is driving the EBITDA trajectory for COMPASS Pathways plc (CMPS), reflecting the company's current lack of commercial sales. This indicator measures net cash flow from core operations before depreciation and interest, enabling an assessment of real operational efficiency and the capital burn rate, which is critical for high-risk biotech assets in the development stage.